SuperworthInnoviva EPS INVA
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $4.08
- Latest quarter, Q2 FY26
- −$1.14
- −248% on a year earlier
- Fiscal year 2025
- $3.03
- +2425% on the year before
Innoviva's earnings per share was $4.08 over the twelve months to Jun 30, 2026, up 1600% on a year earlier.
In its latest quarter, Q2 FY26, it was −$1.14, down 248% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 9% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $3.03 | +2425% |
| FY2024 | $0.12 | −94% |
| FY2023 | $2.14 | +3% |
| FY2022 | $2.07 | −25% |
| FY2021 | $2.77 | +38% |
| FY2020 | $2.01 | +41% |
| FY2019 | $1.43 | −59% |
| FY2018 | $3.53 | +204% |
| FY2017 | $1.16 | +152% |
| FY2016 | $0.46 | n/a |
| FY2015 | −$0.16 | n/a |
| FY2014 | −$1.52 | n/a |
| FY2013 | −$1.66 | n/a |
| FY2012 | −$0.19 | n/a |
| FY2011 | −$1.41 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.14 | −248% | $4.08 | |
| Q1 FY26 | $2.22 | n/a | $5.99 | |
| Q4 FY25 | $1.92 | +911% | $3.03 | |
| Q3 FY25 | $1.08 | +5300% | $1.30 | |
| Q2 FY25 | $0.77 | n/a | $0.24 | |
| Q1 FY25 | −$0.74 | −261% | −$1.08 | |
| Q4 FY24 | $0.19 | −74% | $0.12 | |
| Q3 FY24 | $0.02 | −98% | $0.65 | |
| Q2 FY24 | −$0.55 | −2850% | $1.61 | |
| Q1 FY24 | $0.46 | +10% | $2.18 | |
| Q4 FY23 | $0.72 | n/a | $2.14 | |
| Q3 FY23 | $0.98 | −65% | $0.44 |
Against its peers
Companies in Drug Manufacturers - General nearest Innoviva's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| INVAInnoviva | $4.08 | +1600% a year |
| ANABAnaptysbio | $4.57 | |
| PCRXPacira BioSciences | $0.35 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| ANIPANI Pharmaceuticals | $4.70 | |
| OMEROmeros | $1.52 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| ABUSArbutus Biopharma | $0.78 | |
| NRIXNurix Therapeutics | $2.31 | |
| Peer median | $2.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Innoviva
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.